Areas of Focus
- Post-translational modifications and metabolic disease mechanisms
- Antibody and small molecule drug development based on targets
Work Experience
- 2015.8~2017.6 Postdoctoral Researcher, Basic Medical College, Wuhan University
- 2017.7~2021.7 Assistant Researcher, Zhongnan Hospital of Wuhan University
- 2021.8~present Distinguished Researcher, Basic Medical College, Wuhan University
Academic Background & Achievements
- 2005.9~2009.6 Bachelor in Bioengineering: Chengdu University of Technology
- 2009.9~2015.7 PhD in Genetics: Wuhan University
Publications
- A kinome screen reveals that Nemo-like Kinase is a key upstream regulator of hepatic gluconeogenesis, Ji YX et al., 2021
- Hepatic Regulator of G protein Signaling 5 Ameliorates NAFLD by Suppressing TAK1-JNK/p38 Signaling, Wang J et al., 2020
- Milk Fat Globule–Epidermal Growth Factor–Factor 8 Improves Hepatic Steatosis and Inflammation, Zhang L et al., 2020
- Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes, Cheng X et al., 2020
- F-box/WD Repeat-Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal-Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice, Bai L et al., 2019
- Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3, Fang J et al., 2019
- The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis, Ji YX et al., 2018
- Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates, Wang PX et al., 2017
- The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling, Ji YX et al., 2016
- Suppressor of IKKvarepsilon is an essential negative regulator of pathological cardiac hypertrophy, Deng KQ et al., 2016